Ivermectin decreases inflammation and imiquimod–induced psoriasis-like skin lesions in rat via targeting TLR4 / p65 NF-κB

Document Type : Original Article

Authors

1 Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Research Group on Community Nutrition and Oxidative Stress (NUCOX) and Health Research Institute of Balearic Islands (IdISBa), University of Balearic Islands-IUNICS, Palma de Mallorca E-07122, Balearic Islands, Spain

3 CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain

10.22038/ijbms.2025.83254.18008

Abstract

Objective(s): Psoriasis is a chronic skin disease that usually manifests as white and silver spots on the skin. Because of its anti-inflammatory properties, we investigated the effects of ivermectin (IVM) on imiquimod (IMQ)-induced psoriasis in rats.
Materials and Methods: Fifteen rats were assigned to 3 different groups (n=5 per group): the control group received normal water and food; the psoriasis group, in which psoriasis was induced by topical application of IMQ (1 mg per rat), and treatment group where rats were treated daily with topical IVM-gel (1%) from day 3 to 7. The Psoriasis Area Severity Index (PASI) Score for the entire treatment period was used to assess erythema, silver scale, and skin thickness on the dorsal region of rats, and the spleen-to-body weight index on day 7 was examined. Moreover, histological assessment of skin tissues was performed using fluorescence immunostaining and hematoxylin-eosin (H&E) staining. 
Results: The severity of lesions in the ivermectin group was reduced compared to the IMQ group, with a significant decrease in the average PASI scores. The results of fluorescence immunostaining showed that topical administration of IVM-gel reduced inflammation by decreasing Toll-like receptor 4 (TLR4) levels and p65 nuclear factor kappa-B (NF-κB). Furthermore, findings from H&E staining revealed that IVM-gel decreased dermal fibrosis, epidermal thickness, and infiltration of inflammatory cells caused by IMQ. 
Conclusion: Based on the obtained results, it can be concluded that IVM-gel can effectively reduce psoriasis lesions due to its therapeutic properties, such as anti-inflammatory effects via targeting TLR4/p65 NF-κB. 

Keywords

Main Subjects

References

1. Chen S, Li H, Liu Y, Zhu Z, Wei Q. Quercitrin extracted from tartary buckwheat alleviates imiquimod-induced psoriasis-like dermatitis in mice by inhibiting the Th17 cell response. J Funct Foods 2017;38:9-19.
2. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017;76:377-90.
3. Kaffenberger BH, Lee GL, Tyler K, Chan DV, Jarjour W, Ariza ME, et al. Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother 2014;10:876-86.
4. Unissa R, Kumar PM, Pasha M, Begum S, Maheswari B. Psoriasis: A comprehensive review. Asian J Pharm Sci 2019;9:29-38.
5. Chen Y, Zhang Q, Liu H, Lu C, Liang C-L, Qiu F, et al. Esculetin ameliorates psoriasis-like skin disease in mice by inducing CD4+ Foxp3+ regulatory T cells. Front Immunol 2018;9:2092-2104.
6. Ansar A, Emami Z. Evaluation of serum prolactin level in patients with psoriasis. Avicenna J Clin Med 2015;22:43-47.
7. Sangaraju R, Alavala S, Nalban N, Jerald MK, Sistla R. Galangin ameliorates imiquimod-induced psoriasis-like skin inflammation in BALB/c mice via down regulating NF-κB and activation of Nrf2 signaling pathways. Int Immunopharmacol 2021;96:107754. 
8. Kurschus FC, Moos S. IL-17 for therapy. J Dermatol Sci 2017;87:221-227.
9. Yousefi-Manesh H, Noori T, Asgardoon MH, Derakhshan MH, Tavangar SM, Sheibani M, et al. Protective effect of dapsone against bleomycin-induced lung fibrosis in rat. Exp Mol Pathol 2022;124:104737.
10. Tanhapour M, Falahi B, Vaisi‐Raygani A, Bahrehmand F, Kiani A, Rahimi Z, et al. Angiotensin‐converting enzyme insertion/deletion (rs106180) and angiotensin type 1 receptor A1166C (rs106165) genotypes and psoriasis: correlation with cellular immunity, lipid profile, and oxidative stress markers. J Cell Biochem 2019;120:2627-2633.
11. Nie L, Cai S-Y, Shao J-Z, Chen J. Toll-like receptors, associated biological roles, and signaling networks in non-mammals. Front immunol 2018;9:1523-1541.
12. Chen J-Q, Szodoray P, Zeher M. Toll-like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol 2016;50:1-17.
13. Botten G, Scumpia P, Doty K, Smale S. Global regulation of Toll-like receptor 4-induced inflammatory gene networks by physiologic stress signals in macrophages. Am Assoc Immnol 2015; 194: 194-213.
14. Panzer R, Blobel C, Fölster‐Holst R, Proksch E. TLR 2 and TLR 4 expression in atopic dermatitis, contact dermatitis and psoriasis. Exp Dermatol 2014;23:364-366.
15. Pochernina VV, Daschuk AM. TLR expression on peripheral blood monocytes in patients with psoriasis. Wiad Lek 2020; 73:401-404.
16. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620-628.
17. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017; 2:17023-17031.
18. Ortiz-Lopez LI, Choudhary V, Bollag WB. Updated perspectives on keratinocytes and psoriasis: Keratinocytes are more than innocent bystanders. Psoriasis (Auckl) 2022;12:73-87.
19. Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis 2022;13:81-93.
20. Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res 2020; 53:48-59.
21. Goldminz A, Au S, Kim N, Gottlieb A, Lizzul P. NF-κB: An essential transcription factor in psoriasis. J Dermatol Sci 2013; 69:89-94.
22. Andrés RM, Montesinos MC, Navalón P, Payá M, Terencio MC. NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: In vitro and in vivo effects of BTH. JID Innov 2013; 133:2362-2371.
23. El Malki K, Karbach SH, Huppert J, Zayoud M, Reißig S, Schüler R, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. JID Innov 2013;133:441-451.
24. Hammerl V, Parlar B, Navarini A, Gantenbein L, Väth H, Mueller SM. Mucosal side effects in patients treated with topical imiquimod—A scoping review of the literature. Dermatol Ther 2021;34:14355.
25. Sinx KA, Nelemans PJ, Kelleners-Smeets NW, Winnepenninckx VJ, Arits AH, Mosterd K. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial. J Am Acad Dermatol 2020; 83:469-476.
26. Sharma M, Sharma G, Singh B, Katare O. Actinic keratosis and imiquimod: A review of novel carriers and patents. Expert Opin Drug Deliv 2019;16:101-112.
27. Chamcheu JC, Chaves-Rodriquez M-I, Adhami VM, Siddiqui IA, Wood GS, Longley BJ, et al. Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model. Acta Derm Venereol 2016; 96:854-856.
28. Zeng Y, Zhao H, Zhang T, Zhang C, He Y, Du L, et al. Curcumin against imiquimod-induced psoriasis of mice through IL-6/STAT3 signaling pathway. Biosci Rep 2020; BSR20192842.
29. Jabeen M, Boisgard A-S, Danoy A, El Kholti N, Salvi J-P, Boulieu R, et al. Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics 2020; 12:789-807.
30. Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin Drug Deliv 2012;9:783-804.
31. Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv 2014; 11:1833-1847.
32. Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv 2010; 7:977-992.
33. Padivitage N, Adhikari S, Rustum AM. Assay of ivermectin including determination and identification of its related substances in ivermectin injectable product by a stability-indicating RP-HPLC method. Chromatographia 2021; 84:989-997.
34. Laing R, Gillan V, Devaney E. Ivermectin–old drug, new tricks?. Trends Parasitol 2017; 33:463-472.
35. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. BioMed Central 2020; 19: 1-5.
36. Yan S, Ci X, Chen N, Chen C, Li X, Chu X, et al. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res 2011; 60: 589-596.
37. Ventre E, Rozières A, Lenief V, Albert F, Rossio P, Laoubi L, et al. Topical ivermectin improves allergic skin inflammation. Allergy 2017; 72:1212-1221.
38. Schaller M, Gonser L, Belge K, Braunsdorf C, Nordin R, Scheu A, et al. Dual anti‐inflammatory and anti‐parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol 2017; 31:1907-1911.
39. Thibaut de Ménonville S, Rosignoli C, Soares E, Roquet M, Bertino B, Chappuis J-P, et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models. Dermatol Ther 2017; 7:213-225.
40. Hebeish A, Hashem M, Abd El-Hady M, Sharaf S. Development of CMC hydrogels loaded with silver nano-particles for medical applications. Carbohydr Polym 2013; 92:407-413.
41. Basu P, Repanas A, Chatterjee A, Glasmacher B, NarendraKumar U, Manjubala I. PEO–CMC blend nanofibers fabrication by electrospinning for soft tissue engineering applications. Mater Lett 2017; 195:10-3.
42. Basu P, Narendrakumar U, Arunachalam R, Devi S, Manjubala I. Characterization and evaluation of carboxymethyl cellulose-based films for healing of full-thickness wounds in normal and diabetic rats. ACS omega 2018; 3:12622-12632.
43. Ahmad H. Celluloses as support materials for antibacterial agents: a review. Cellulose 2021;28:2715-2761.
44. Rahman M, Hasan M, Nitai AS, Nam S, Karmakar AK, Ahsan M, et al. Recent developments of carboxymethyl cellulose. Polymers 2021;13:1345-1392.
45. Costa EM, Pereira CF, Ribeiro AA, Casanova F, Freixo R, Pintado M, et al. Characterization and evaluation of commercial carboxymethyl cellulose potential as an active ingredient for cosmetics. Appl Sci 2022; 12:6560-6575.
46. Zhang W, Liu Y, Xuan Y, Zhang S. Synthesis and applications of carboxymethyl cellulose hydrogels. Gels 2022; 8:529-537.
47. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-110.
48. Saka R, Jain H, Kommineni N, Chella N, Khan W. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB/c mice. J Drug Deliv Technol 2020; 58:101691.
49. Maher A, Radwan R, Breitinger H-G. In vivo protection against strychnine toxicity in mice by the glycine receptor agonist ivermectin. Biomed Res Int 2014; 2014:640790.
50. Zeini MS, Haddadi N-S, Shayan M, Zeini MS, Kazemi K, Solaimanian S, et al. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. Int Immunopharmacol 2021; 100:108160.
51. Yousefi-Manesh H, Dehpour AR, Nabavi SM, Khayatkashani M, Asgardoon MH, Derakhshan MH, et al. Therapeutic effects of hydroalcoholic extracts from the ancient apple mela rosa dei monti sibillini in transient global ischemia in rats. Pharmaceuticals 2021; 14:1106-1118.
52. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: A comprehensive review. J Autoimmun 2015; 64:66-73.
53. Branisteanu DE, Voicu CM, Cretu A, Dimitriu A, Luca MC, Salavastru CM. Adverse reactions of biological therapy for psoriasis. Med Surg J 2015; 119:38-44.
54. Meng FZ, Liu JB, Wang X, Wang P, Hu WH, Hou W, et al. TLR7 activation of macrophages by imiquimod inhibits hiv infection through modulation of viral entry cellular factors. Biology 2021;10:661-677.
55. Moos S, Mohebiany AN, Waisman A, Kurschus FC. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. J Invest Dermatol 2019;139:1110-1117.
56. Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or immune cells–which is the trigger?. Dermatology 2019; 235:91-100.
57. Garzorz-Stark N, Eyerich K. Psoriasis pathogenesis: keratinocytes are back in the spotlight. J Invest Dermatol 2019; 139:995-996.
58. Alexander H, Nestle FO. Pathogenesis and immunotherapy in cutaneous psoriasis: What can rheumatologists learn?. Curr Opin Rheumatol 2017;29:71-78.
59. Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke W-H, et al. The role of IL‐23 and the IL‐23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017; 31:1616-1626.
60. Jabeen M, Boisgard AS, Danoy A, El Kholti N, Salvi JP, Boulieu R, et al. Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics 2020;12:789-806.
61. Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther 2016; 33:1481-501.
62. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014;13:316-323.
63. Aryannejad A, Tabary M, Noroozi N, Mashinchi B, Iranshahi S, Tavangar SM, et al. Anti-inflammatory effects of ivermectin in the treatment of acetic acid-induced colitis in rats: Involvement of GABAB receptors. Dig Dis Sci 2022; 67:3672-3682.
64. Ye Y, Wang P, Zhou F. miR-489-3p inhibits TLR4/NF-κB signaling to prevent inflammation in psoriasis. Exp Ther Med 2021; 22:744-753.
65. Malan M, Xuejingzi W, Quan SJ. Nuclear factor-kappa B (NF-ҡB) activation gene single nucleotide polymorphisms (SNP) associated with the risk of psoriasis in chinese han people of wuhan, hubei province. Asian J Sci Res 2020;3:46-55.
66. Wei W, Dejie L, Xiaojing S, Tiancheng W, Yongguo C, Zhengtao Y, et al. Magnolol inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. Inflammation 2015; 38:16-26.
67. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?. Br J Dermatol 2020; 182:840-848.
68. Lv J, Wang Y, Xu J, Zhou T, Chen Z, Yang H, et al. Protective effect of Yangxue Jiedu Soup against psoriasis-like lesions by regulating TLR4/NF-κB signaling pathway mediated by secretion of exosome HSP70. Biomed Pharmacother 2022; 147:112604.
69. Cao C, Yin C, Chai Y, Jin H, Wang L, Shou S. Ulinastatin mediates suppression of regulatory T cells through TLR4/NF-κB signaling pathway in murine sepsis. Int Immunopharmacol 2018; 64:411-423.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 6
June 2025
Pages 808-814

Files

Share

How to cite

Statistics